TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30038037
Drug: Empirical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antimicrobial therapy (EAT) including vancomycin and broad-spectrum beta-lactam
Study: 30038037
Drug: Empirical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antimicrobial therapy (EAT)
Study: 30038390
Drug: Combined-intensified-modulated-adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-intensified-modulated-adjuvant treatment including RT and hormone therapy (HT) after RP.
Study: 30038794
Drug: Multi-modal frailty
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modal frailty intervention (tailored exercise program, protein supplementation, vitamin D supplementation, medication review)
Study: 30039554
Drug: Gilteritinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gilteritinib (20 to 300 mg/d, once daily)
Study: 30039634
Drug: Brexpiprazole 1
Normalized name: brexpiprazole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 1 to 3 mg/day adjunct to current ADT
Study: 30040168
Drug: Prexasertib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prexasertib (80 mg/m)
Study: 30041614
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by adjuvant chemotherapy (reference treatment)
Study: 30041962
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation therapy (NCRT)
Study: 30043115
Drug: Florbetaben injection
Normalized name: florbetaben
DrugBank: Florbetaben F-18 (DB09148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Florbetaben injection (222-318.2 MBq, mean 270.1 ± 33.3 MBq)
Study: 30043210
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks with methotrexate
Study: 30044478
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for stage I seminoma (65 patients, 42.2%)
Study: 30044478
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for high-risk stage I non-seminoma (23 patients)
Study: 30044478
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for stage II seminoma (14 patients, 53.8%)
Study: 30044478
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for stage III seminoma (all patients)
Study: 30044478
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for stage II and III non-seminoma (all patients)
Study: 30044693
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment for IKZF1 deletion
Study: 30045838
Drug: Vadastuximab talirine
Normalized name: Vadastuximab talirine
DrugBank: Vadastuximab talirine (DB11884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadastuximab talirine (10 μg/kg) administered intravenously on the last day of hypomethylating agent (HMA) infusion (azacitidine or decitabine) in 4-week cycles.
Study: 30046307
Drug: Kisspeptin-10 administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kisspeptin-10 administration
Study: 30046708
Drug: Idarucizumab (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (up to 5 g as two consecutive intravenous infusions over 5-10 minutes each)
Study: 30046714
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin gel (1120 IU/100 g), administered 2-3 times daily for 16 days
Study: 30051292
Drug: Patient management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient management and treatment improvements
Study: 30051298
Drug: Daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of a water-based, peelable nail polish
Study: 30051298
Drug: 5% amorolfine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% amorolfine nail lacquer (weekly application)
Study: 30052269
Drug: Alectinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib (300 mg single dose) in moderate hepatic impairment (n = 8)
Study: 30052269
Drug: Alectinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib (300 mg single dose) in severe hepatic impairment (n = 8)
Study: 30053006
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg apatinib once a day (q.d.)
Study: 30053006
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg apatinib once a day (q.d.)
Study: 30053905
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg BID for 6 weeks followed by HD IL-2 (600,000 IU/kg every 8 hours on days 1-5 and days 15-19)
Study: 30053953
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity (number of steps per day)
Study: 30054122
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 8 mg/kg every 4 weeks for 3 months as an add-on to glucocorticoids (prednisone starting at 0.7 mg/kg/day)
Study: 30054977
Drug: Continued Appropriate
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued Appropriate Medical Therapy (CAMT)
Study: 30055091
Drug: Antimalarial agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimalarial agents
Study: 30055573
Drug: Intranasal challenge
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal challenge with wild-type influenza A/H1N1pdm virus
Study: 30055613
Drug: Steroids, immunosuppressants,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids, immunosuppressants, N-Acetylcysteine
Study: 30055633
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard pharmacological treatment)
Study: 30055824
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of inhaled nemiralisib (100 μg)
Study: 30055824
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of inhaled nemiralisib (200 μg)
Study: 30055824
Drug: Repeat dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dose of inhaled nemiralisib (200 μg for 10 days)
Study: 30055824
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of inhaled nemiralisib (200 μg) with charcoal block
Study: 30055837
Drug: Genotyping for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotyping for JS and complete age-appropriate ophthalmic examinations
Study: 30056385
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention physiotherapy (treatment within 2 weeks after randomisation)
Study: 30056385
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (treatment 6 weeks postrandomisation)
Study: 30057012
Drug: Conivaptan (vasopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan (vasopressin V1A/V2 receptor antagonist)
Study: 30060061
Drug: LY3039478 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3039478 (oral dose: 2.5-100 mg, thrice weekly on a 28-day cycle)
Study: 30060061
Drug: LY3039478 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3039478 (oral dose: 45-100 mg)
Study: 30060083
Drug: Venetoclax (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (800 mg daily continuously) in combination with bendamustine-rituximab (BR) given for six cycles at standard doses
Study: 30060083
Drug: Venetoclax (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (800 mg daily continuously) in combination with bendamustine-rituximab (BR)
Study: 30060328
Drug: Hypothyroidism treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothyroidism treatment
Study: 30060328
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hypothyroidism treatment)
Study: 30061026
Drug: Vaccine Hesitancy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine Hesitancy Scale (VHS) survey tool
Study: 30061051
Drug: Pfs25H-EPA/Alhydrogel 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfs25H-EPA/Alhydrogel 16 μg (pilot cohort)
Study: 30061051
Drug: Pfs25H-EPA/Alhydrogel 47
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfs25H-EPA/Alhydrogel 47 μg (main cohort)
Study: 30061051
Drug: Pfs25H-EPA/Alhydrogel (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfs25H-EPA/Alhydrogel (after fourth dose)
Study: 30061051
Drug: Pfs25H-EPA/Alhydrogel (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfs25H-EPA/Alhydrogel (after third dose)
Study: 30061429
Drug: On-site monthly
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site monthly screenings of cardiovascular risk factors
Study: 30061431
Drug: Pyridostigmine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (2 mg/kg/day to 6 mg/kg/day in four daily doses)
Study: 30062043
Drug: Personalized intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personalized intervention including reminders (audio and/or visual) and text message or automated phone call if a dose of medication is not taken within a pre-specified time frame.
Study: 30062746
Drug: Higher opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher opioid dose
Study: 30063383
Drug: MRI-guided stereotactic
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided stereotactic body radiation therapy (SBRT) up to a dose of 24 Gy in three fractions in 1 week
Study: 30064401
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (wP) 40 to 75 mg/m² in combination with oral metronomic cyclophosphamide (OMC) 50 mg twice a day
Study: 30064401
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic cyclophosphamide (OMC) 50 mg twice a day
Study: 30064418
Drug: Depression screening
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depression screening and treatment integrated into HIV care initiation
Study: 30064457
Drug: Log-HOMA-IR (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Log-HOMA-IR (insulin resistance)
Study: 30064466
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral intervention administered through a smartphone app (CBIA)
Study: 30064466
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral intervention administered through a smartphone app plus telephone conference calls (CBIA + TCC)
Study: 30065032
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion during a mixed-nutrient meal
Study: 30065032
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion during a mixed-nutrient meal
Study: 30065032
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no infusion) during a mixed-nutrient meal
Study: 30065100
Drug: MEDI3726 (ADCT-401),
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI3726 (ADCT-401), an antibody-drug conjugate targeting PSMA, consisting of an engineered anti-PSMA antibody J591 conjugated to the pyrrolobenzodiazepine (PBD) dimer tesirine.
Study: 30065943
Drug: Spa treatment
Normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa treatment (3 weeks, 15 days of treatment, 120 to 150 minutes a day)
Study: 30067493
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Anesthesia (GA) using single bolus propofol (mean dose 2.1 ± 0.3 mg/kg) and sevoflurane
Study: 30067922
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion test (copeptin cutoff >4.9 pmol per liter)
Study: 30067922
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion test
Study: 30068301
Drug: Neuroprotective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroprotective treatment with hypothermia
Study: 30068505
Drug: Obinutuzumab plus
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab plus lenalidomide (20 mg)
Study: 30070770
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FF and BAT
Study: 30070770
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of FF and BAT
Study: 30071865
Drug: ENMD-2076 250
Normalized name: ENMD-2076 free base
DrugBank: ENMD-981693 (DB16891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENMD-2076 250 mg orally once daily with continuous dosing in 4-week cycles until disease progression or unacceptable toxicity.
Study: 30073432
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/day for at least 7 consecutive days)
Study: 30073583
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg bid plus docetaxel 75 mg/m²
Study: 30073642
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg) administered intravenously every 3 weeks until progression or unacceptable toxicity.
Study: 30074111
Drug: Beta-Blockers (BB)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Blockers (BB)
Study: 30074111
Drug: ACE Inhibitors/Angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE Inhibitors/Angiotensin Receptor Blockers (ACEi/ARB)
Study: 30074259
Drug: Glasdegib 100
Normalized name: glasdegib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib 100 mg orally, once daily in continuous 28-day cycles from day -3, plus intravenous cytarabine 100 mg/m².
Study: 30074259
Drug: Cytarabine/daunorubicin (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine/daunorubicin (as part of the combination therapy).
Study: 30076280
Drug: MRD-directed IFN-α
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRD-directed IFN-α treatment
Study: 30077125
Drug: Atezolizumab 1-20
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1-20 mg/kg or 1200 mg intravenously every 3 weeks
Study: 30079582
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) drug levels < 200 ng/ml or undetectable desethylchloroquine
Study: 30079582
Drug: Self-administered questionnaires
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaires (MASRI < 80%)
Study: 30081223
Drug: EG Scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG Scan II (transnasal capsule endoscope)
Study: 30081838
Drug: Ongoing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing treatment with zidovudine (76% of children, median duration 48 months (26-74))
Study: 30081838
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment with stavudine (18% of children, median treatment duration 8 months (5-25))
Study: 30081838
Drug: Ongoing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing treatment with lopinavir/ritonavir (27% of children, median duration 49 months (23-59))
Study: 30081846
Drug: Decision aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision aid administered prior to specialist consultation
Study: 30081846
Drug: Decision aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision aid administered within the consultation
Study: 30081846
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both decision aids
Study: 30081867
Drug: Quizartinib 135
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib 135 mg/day
Study: 30081867
Drug: Quizartinib 90
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib 90 mg/day
Study: 30081867
Drug: Quizartinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quizartinib (both doses)
Study: 30081937
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of smoking, exercise habits, BMI, trust in treatment, and satisfaction with care
Study: 30082340
Drug: SH003 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SH003 (1 to 4 tablets, three times a day for 3 weeks)
Study: 30082340
Drug: SH003 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: SH003 (dose escalation)
Study: 30082349
Drug: Sorbitol syrup
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol syrup (control)
Study: 30082474
Drug: Single-agent options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent options
Study: 30082475
Drug: Alisertib 50
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 50 mg b.i.d. plus rituximab 375 mg/m2
Study: 30082475
Drug: Alisertib 40
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 40 mg b.i.d. plus rituximab and vincristine
Study: 30083405
Drug: Treatment modality
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment modality and compliance
Study: 30084702
Drug: 10-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-valent pneumococcal conjugate vaccine
Study: 30084943
Drug: Efavirenz 400
Normalized name: efavirenz 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 400 mg (EFV400) coadministered with Isoniazid (INH) and Rifampicin (RIF) after 4 weeks (PK2)
Study: 30084943
Drug: Efavirenz 400
Normalized name: efavirenz 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 400 mg (EFV400) coadministered with Isoniazid (INH) and Rifampicin (RIF) after 12 weeks (PK3)
Study: 30084943
Drug: Efavirenz 400
Normalized name: efavirenz 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 400 mg (EFV400) without coadministration (PK1)
Study: 30085139
Drug: 2-dose schedule
Normalized name: hepatitis A vaccine (inactivated) strain HM175
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose schedule of bivalent HPV vaccine (bHPV)
Study: 30085139
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of either bivalent HPV vaccine (bHPV) or quadrivalent HPV vaccine (qHPV)
Study: 30085139
Drug: 3-dose schedule
Normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose schedule of bivalent HPV vaccine (bHPV)
Study: 30086261
Drug: Small-bowel capsule
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-bowel capsule endoscopy (CE)
Study: 30086777
Drug: Ruxolitinib 10
Normalized name: ruxolitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 10 mg BID, with incremental increases of 5 mg BID at weeks 12 and 18 (maximum 20 mg BID)
Study: 30086778
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment arm (paper-based hypertension treatment guidelines)
Study: 30087028
Drug: Momelotinib 150
Normalized name: momelotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib 150 mg twice daily combined with trametinib 1.0 mg once daily
Study: 30087093
Drug: Usual clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual clinical treatment (UCT) group
Study: 30087197
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication availability in the home
Study: 30087197
Drug: Medication readiness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication readiness criteria
Study: 30087197
Drug: Controller medication
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controller medication availability in the home
Study: 30087197
Drug: Controller medication
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controller medication readiness criteria
Study: 30444686
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of chemotherapy
Study: 30088048
Drug: Afatinib 20
Normalized name: afatinib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 20 mg/day with Carboplatin AUC6 (A/C)
Study: 30088048
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg/day with Carboplatin AUC6 (A/C)
Study: 30088048
Drug: Afatinib 20
Normalized name: afatinib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 20 mg/day with Carboplatin AUC6 and Paclitaxel 175 mg/m2 (A/C/P)